Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Lilly's CYRAMZA (ramucirumab) significantly improved overall survival in phase 3 non-small cell lung cancer study. Results from the REVEL trial were published in The Lancet and also presented at ASCO ...

Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the ...

Novartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial. A phase 3 study testing Eli Lilly’s Verzenio ...

Officials at Eli Lilly say that SQUIRE, a recently completed Phase III study, met its primary endpoint. The trial found that patients with stage IV metastatic squamous non-small cell lung cancer ...

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. This story was originally published on BioPharma Dive. To ...